U.S. markets open in 7 hours 35 minutes
  • S&P Futures

    4,232.50
    +7.25 (+0.17%)
     
  • Dow Futures

    34,775.00
    +89.00 (+0.26%)
     
  • Nasdaq Futures

    13,716.25
    +6.50 (+0.05%)
     
  • Russell 2000 Futures

    2,271.80
    +3.90 (+0.17%)
     
  • Crude Oil

    65.27
    +0.37 (+0.57%)
     
  • Gold

    1,838.30
    +7.00 (+0.38%)
     
  • Silver

    27.91
    +0.43 (+1.58%)
     
  • EUR/USD

    1.2160
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5770
    0.0000 (0.00%)
     
  • Vix

    16.69
    -1.70 (-9.24%)
     
  • GBP/USD

    1.4046
    +0.0056 (+0.40%)
     
  • USD/JPY

    108.8320
    +0.2500 (+0.23%)
     
  • BTC-USD

    58,975.65
    +496.93 (+0.85%)
     
  • CMC Crypto 200

    1,565.73
    +129.95 (+9.05%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,539.01
    +181.19 (+0.62%)
     

CEPI, VBI Vaccines Collaborate To Develop COVID-19 Vaccine Candidates Against Variants

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIVentered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the South African B.1.351 variant, also known as 501Y.V2.

  • CEPI is an international coalition set up to prepare for future infectious disease threats.

  • It will provide up to $33 million to support the advancement of VBI-2905, a monovalent eVLP candidate, through Phase 1 development. Phase 1 trial will start in mid-year 2021.

  • As part of the agreement, this funding will also support the preclinical expansion of additional multivalent vaccine candidates. 

  • VBI Vaccines is advancing a suite of coronavirus vaccine candidates under the VBI-2900 program, developed in collaboration with the National Research Council of Canada.

  • An adaptive Phase 1/2 study of VBI-2902 is already ongoing at nine clinical sites in Canada.

  • Price Action: VBIV shares are up 10.2% at $3.47 in premarket trading on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.